Back to results
US 2025/0017930 A1Published application
Pharmaceutical compositions comprising azd9291
OwnerCindy FINNIE, Steven Anthony RAW +1inventors
InventorsCindy FINNIE, Steven Anthony RAW, David WILSON
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
Claims14
A pharmaceutical composition comprising:
- (a) from 2 to 70 parts of the Agent;
- (b) from 5 to 96 parts of two or more pharmaceutical diluents;
- (c) from 0 to 15 parts of one or more pharmaceutical disintegrants;
- (d) from 0 to 1.5 parts of one or more pharmaceutical solubilising agents;
- and
- (c) from 0 to 3 parts of one or more pharmaceutical lubricants;
- wherein all parts are by weight and the sum of the parts (a)+(b)+(c)+(d)+(e)=100;
- wherein one of the two or more pharmaceutical diluents is microcrystalline cellulose wherein the microcrystalline cellulose makes up from 7 to 30 wt % of the two or more pharmaceutical diluents (b);
- and wherein the Agent is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide or a pharmaceutically acceptable salt thereof.
6 more elements
Dependencies are inferred from the claim text.